Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
Information source: Shanghai Jiao Tong University School of Medicine
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: montelukast (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Shanghai Jiao Tong University of Medicine Official(s) and/or principal investigator(s):
hong jianguo, prof, Principal Investigator, Affiliation: pediatric of shanghai jiantong University
Overall contact:
Hong jianguo, prof, Phone: 13386259530, Email: hongjianguo@hotmail.com
Summary
The aim of this study was to determine the effects of lower dose Montelukast on the
expression and variation of TGF-β in induced sputum and T lymphocyte for children with mild
persistent Asthma.
Clinical Details
Study design: Cross-Sectional, Case Control, Prospective Study
Detailed description:
The majority pediatric asthma patients in Shanghai are mild persistent asthma. These
patients require controller medications every day to achieve and maintain control.
Leukotriene receptor antagonist is one of the options which have been recommended to use as
a mono controller therapy. Patient satisfaction and compliance was better with montelukast,
attributed to oral intake and convenience. Owing to its easy and simple oral once a day
administration montelukast was found to be advantageous over ICS. On the other hand, recent
studies have shown that there is a considerable degree of airway remodeling in peripheral
airways in patients with mild asthma. The new information points out the need for large,
long-term studies on the treatment of mild persistent asthma, with an emphasis on
exacerbations, remodeling, and the relationship between these outcomes and markers of asthma
control. TGF- β participates in the initiation and propagation of inflammatory and immune
responses in the airways. The leukotrienes exert their biologic actions by binding to and
activating specific receptors. Montelukast, a cysteinyl leukotriene 1 (CysLT1) receptor
antagonist, acts on LTC4, LTD4 and LTE4, and, therefore, on airway inflammation and
bronchoconstriction. Some results suggest that low dose of Montelukast may modulate the
parameters of inflammation and fibrosis. In this study we try to determine the effects of
lower dose Montelukast on the expression and variation of TGF-β in induced sputum and T
lymphocyte for children with mild persistent Asthma.
Drug in the study provide by MSD. We have done induced sputum procedure in our past study.
Reagent can be bought from company.
Eligibility
Minimum age: 6 Years.
Maximum age: 14 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients aged 6 to 14 years with a history of physician-diagnosed asthma (at least 3
episodes of asthma symptoms during the previous year, including, but not limited to
cough, wheezing, and shortness of breath)
Exclusion Criteria:
- Patients were not in good health, other than asthma, on the basis of results of
medical history, physical examination, and routine laboratory tests.
Locations and Contacts
Hong jianguo, prof, Phone: 13386259530, Email: hongjianguo@hotmail.com Additional Information
Starting date: September 2007
Ending date: December 2009
Last updated: September 27, 2007
|
